Researchers at McGill University Health Center find that active surveillance of men with low-risk prostate cancer may be better for quality of life and is cost-effective compared with immediate treatment.

According to a study published in in Canadian Medical Association’s CMAJ Open, researchers found that active surveillance with follow-up over five years could save about $96 million CDN at the national level because the high cost of treating cancer that was at low risk of progressing could be avoided. With active surveillance, the cost per patient for the first year and the subsequent five years of follow-up was estimated at $6,200 compared with $13,735 for immediate treatment.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access